APA (7th ed.) Citation

C, K., J, K., JE, S., SH, L., KM, K., DG, K., . . . ST, K. (2026). Prognostic implications of tissue-based homologous recombination deficiency in metastatic gastric cancer treated with immune checkpoint inhibitor plus chemotherapy. Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association, 29(4), 816. https://doi.org/10.1007/s10120-026-01755-6

Chicago Style (17th ed.) Citation

C, Kim, Kim J, Shin JE, Lim SH, Kim KM, Kim DG, Lee J, and Kim ST. "Prognostic Implications of Tissue-based Homologous Recombination Deficiency in Metastatic Gastric Cancer Treated with Immune Checkpoint Inhibitor Plus Chemotherapy." Gastric Cancer : Official Journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association 29, no. 4 (2026): 816. https://doi.org/10.1007/s10120-026-01755-6.

MLA (9th ed.) Citation

C, Kim, et al. "Prognostic Implications of Tissue-based Homologous Recombination Deficiency in Metastatic Gastric Cancer Treated with Immune Checkpoint Inhibitor Plus Chemotherapy." Gastric Cancer : Official Journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association, vol. 29, no. 4, 2026, p. 816, https://doi.org/10.1007/s10120-026-01755-6.